Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jonsson Comprehensive Cancer Center
PRIMARY OBJECTIVES:
I. To determine whether positron emission tomography (PET) using the new imaging agent 18F-clofarabine can be used for imaging cancer, and whether interventions that activate the immune system can change the biodistribution of 18F-clofarabine.
OUTLINE:
Patients receive 18F-clofarabine intravenously (IV) and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
No restrictions based on gender or racial/ethnic background
You may not be if
Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge
Clareo Health | 18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
